Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 501

1.

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.

Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA.

AIDS. 2009 Jan 28;23(3):279-91. doi: 10.1097/QAD.0b013e32831c54e5. Review.

PMID:
19114854
2.

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, Arranz A, Portilla J, Pasquau J, Iribarren JA, Rubio R, Norton M; OK04 Study Group.

AIDS. 2008 Jan 11;22(2):F1-9.

PMID:
18097218
3.

Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

Pulido F, Delgado R, Pérez-Valero I, González-García J, Miralles P, Arranz A, Hernando A, Arribas JR.

J Antimicrob Chemother. 2008 Jun;61(6):1359-61. doi: 10.1093/jac/dkn103. Epub 2008 Mar 13.

PMID:
18343802
4.

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group.

HIV Med. 2010 Feb;11(2):137-42. doi: 10.1111/j.1468-1293.2009.00752.x. Epub 2009 Aug 13.

5.

Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.

Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K; Study Team.

HIV Med. 2007 Nov;8(8):529-35.

6.

Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, González-García JJ, Cepeda C, Hervás R, Paño JR, Gaya F, Carcas A, Montes ML, Costa JR, Peña JM.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7.

PMID:
16249701
7.

Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.

Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P; ANRS 127 Study Group.

J Antimicrob Chemother. 2009 Jul;64(1):118-25. doi: 10.1093/jac/dkp146. Epub 2009 May 6.

PMID:
19420019
8.

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.

AIDS. 2008 Jan 30;22(3):385-93. doi: 10.1097/QAD.0b013e3282f3f16d.

PMID:
18195565
9.

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.

J Antimicrob Chemother. 2008 Jan;61(1):200-5. Epub 2007 Nov 13.

PMID:
17999977
10.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM; SPIRAL Study Group.

AIDS. 2010 Jul 17;24(11):1697-707. doi: 10.1097/QAD.0b013e32833a608a. Erratum in: AIDS. 2010 Oct 23;24(16):2602.

PMID:
20467288
11.

Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.

Lichterfeld M, Wöhrmann A, Schmeisser N, Fätkenheuer G, Salzberger B, Wyen C, Schmitz K, Sauerbruch T, Rockstroh JK.

Eur J Med Res. 2003 Feb 21;8(2):56-60.

PMID:
12626282
12.

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, Pérez-Elias MJ, Iribarren JA, Rubio R, Ocampo A, Sánchez-Conde M, Knobel H, Arazo P, Sanz J, López-Aldeguer J, Montes ML, Pulido F; OK04 Study Group.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52. doi: 10.1097/QAI.0b013e3181a56de5.

PMID:
19349870
13.

Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.

Sahali S, Chaix ML, Delfraissy JF, Ghosn J.

AIDS Rev. 2008 Jan-Mar;10(1):4-14. Review.

PMID:
18385776
14.

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.

Cohen C, Nieto-Cisneros L, Zala C, Fessel WJ, Gonzalez-Garcia J, Gladysz A, McGovern R, Adler E, McLaren C; BMS AI424-043 Study Group.

Curr Med Res Opin. 2005 Oct;21(10):1683-92.

PMID:
16238909
15.
16.

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, Japour AJ, Danner S, Boucher C, Molla A, Leonard JM.

AIDS. 1998 Mar 26;12(5):F9-14.

PMID:
9543434
17.

Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.

Arnaiz JA, Mallolas J, Podzamczer D, Gerstoft J, Lundgren JD, Cahn P, Fätkenheuer G, D'Arminio-Monforte A, Casiró A, Reiss P, Burger DM, Stek M, Gatell JM; BEST Study Team.

AIDS. 2003 Apr 11;17(6):831-40.

PMID:
12660530
18.

Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.

Moltó J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B.

J Antimicrob Chemother. 2007 Aug;60(2):436-9. Epub 2007 Jun 7.

PMID:
17556354
19.

Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.

Karlström O, Josephson F, Sönnerborg A.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):417-22.

PMID:
17159658
20.

[Lopinavir/ritonavir monotherapy. Possible indications].

López Aldeguer J.

Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 16:21-3. Review. Spanish.

PMID:
19572440

Supplemental Content

Support Center